Teaming up to overcome challenges toward translation of new therapeutics for osteoarthritis

Abstract As a leading global cause of musculoskeletal‐related disability, osteoarthritis (OA) represents a public health urgency. Understanding of disease pathogenesis has advanced substantially in the past decade, yet no disease‐modifying therapeutics have advanced to the clinic. To address this challenge, the CARE‐AP (Cartilage Repair strategies to alleviate Arthritis Pain) collaborative research team was convened to bring together relevant multidisciplinary expertise and perspectives from across the VA research community nationwide. The first CARE‐AP Annual Research Symposium took place (virtually) in February 2022 with roughly 90 participants. A number of innovative and therapeutic strategies were discussed, including siRNA approaches coupled with novel nanoparticle‐based delivery systems, cellular engineering approaches to develop reparative cells that can probe the joint environment and respond to disease‐specific cues, and novel biofabrication techniques to improve tissue engineering and effect “biological joint replacement.” In addition, challenges and advances in rehabilitation approaches, imaging outcomes, and clinical studies were presented, which were integrated into a framework of recommendations for running “preclinical trials” to improve successful clinical translation.